Scarica l'app Stockscreener
2.39
0.84%
0.02
Renovorx Inc Borsa (RNXT) Ultime notizie
RenovoRx (NASDAQ:RNXT) Gains Attention After Compliance Update - Kalkine Media
RenovoRx regains Nasdaq minimum bid price compliance - Investing.com
RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement - Yahoo! Finance Canada
RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath®, an Advanced Dual-Occlusion Catheter, for Targeted Therapeutic Drug-Delivery for Cancer Treatment - Investing News Network
RenovoRx receives U.S. patent allowance for cancer device - Investing.com
RenovoRx receives U.S. patent allowance for cancer device By Investing.com - Investing.com Canada
RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath, an Advanced Dual-Occlusion Catheter for Targeted Therapeutic Drug-Delivery for Cancer Treatment - marketscreener.com
RenovoRx Advances Targeted Localized Therapy for Advanced Pancreatic Cancer - geneonline.com
HC Wainwright Has Positive Outlook of RenovoRx Q3 Earnings - MarketBeat
RenovoRx Eyes 2027 TIGeR-PaC Readout as RenovoCath Expands to 21 Centers - sharewise.com
What is HC Wainwright's Forecast for RenovoRx Q3 Earnings? - MarketBeat
RenovoRx (RNXT) Q2 2026 Earnings: Narrower-than-Expected Loss Drives 11% Share RallyForward Guidance Trends - vinanet.vn
RNXT Q2 2026 Earnings: Narrower Loss Beats Estimate, Shares Jump 11%Share Dilution Risk - vinanet.vn
RenovoRx (NASDAQ:RNXT) Upgraded to "Hold" at Wall Street Zen - MarketBeat
Renovorx Stock Price Forecast. Should You Buy RNXT? - StockInvest.us
H.C. Wainwright Maintains RenovoRx(RNXT.US) With Buy Rating, Maintains Target Price $3 - Moomoo
RenovoRx Inc (NASDAQ: RNXT) Stock Price, News & Analysis - kalkine.ca
RenovoRx earnings beat by $0.02, revenue topped estimates - Investing.com Nigeria
RenovoRx Inc (RNXT) (Q2 2026) Earnings Call Highlights: Record Revenue and Strategic Expansion ... - Yahoo Finance
RenovoRx, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
RenovoRx Q2 Earnings Call Highlights - MarketBeat
RenovoRx (RNXT) Q2 2026 Earnings Call Transcript - AOL.com
RenovoRx Q2 revenue surges 115% YoY to $909,000; raises FY26 guidance - scanx.trade
RenovoRx raises FY26 sales guidance to $3.75M-$4.25M vs $3.2M est - scanx.trade
Earnings call transcript: RenovoRx posts Q2 2026 beat, lifts guidance By Investing.com - Investing.com Canada
RenovoRx Inc reports results for the quarter ended June 30Earnings Summary - TradingView
RenovoRx, Inc. (RNXT) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth - Investing News Network
RenovoRx (NASDAQ:RNXT) Posts Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
Earnings call transcript: RenovoRx posts Q2 2026 beat, lifts guidance - Investing.com
RenovoRx, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
BRIEF-RenovoRx Q2 Net Income USD -2.911 Million - TradingView
Renovorx, Inc. Increases Earnings Guidance for Full Year 2026 - marketscreener.com
RenovoRx completes enrollment in phase III pancreatic cancer trial By Investing.com - Investing.com UK
RenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer - Investing News Network
RenovoRx completes enrollment in phase III pancreatic cancer trial - Investing.com
RenovoRx Inc (RNXT) Q2 2026: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
Renovorx Achieves Major Milestone With Full Enrollment In Phase Iii Tiger-Pac Trial For Locally Advanced Pancreatic Cancer - TradingView
RenovoRx Inc (RNXT) Q2 2026: Everything You Need To Know Ahead O - GuruFocus
RenovoRx pancreatic cancer trial closes enrollment; 78 deaths occurred - Stock Titan
EXCLUSIVE: Renovorx Advances Its Targeted Pancreatic Cancer Therapy, Pivotal Data Expected in 2027 - Yahoo Finance
RenovoRx Inc expected to post a loss of 7 cents a shareEarnings Preview - TradingView
RenovoRx (RNXT) Climbs 3.12% to $1.16 as Oncology Pipeline Keeps Micro-Cap in FocusNarrow Range Breakout - dars.gov.et
RenovoRx reports RenovoCath’s first clinical use in sarcoma - Medical Device Network
RenovoRx Inc (RNXT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
RenovoRx Inc (RNXT) Stock News Today - TradingKey
RenovoRx Announces First Commercial Clinical Use of RenovoCath in Sarcoma Patient Treatment, Marking Expansion of Targeted Drug-Delivery Device to Other Solid Tumors - marketscreener.com
RenovoRx Inc (RNXT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Earnings Preview: RenovoRx to Report Financial Results Post-market on August 12 - Moomoo
RenovoRx’s RenovoCath used in sarcoma treatment for first time By Investing.com - Investing.com Nigeria
RenovoRx’s RenovoCath used in sarcoma treatment for first time - Investing.com
RenovoRx Announces First Commercial Clinical Use of RenovoCath® in Sarcoma Patient Treatment, Marking Expansion of Targeted Drug-Delivery Device to Other Solid Tumors - The Manila Times
A Sarcoma Patient Is Receiving Local Chemotherapy via RenovoCath - Stock Titan
RenovoRx (RNXT) Gains 2.4% to $1.06: Micro-Cap Biotech Presses Against ResistanceCollar Trade - vinanet.vn
RenovoRx Highlights TAMP Platform in Upcoming Oncology Webinar - TipRanks
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):